. 2020 Jun 5;59(12):1627–1639. doi: 10.1007/s40262-020-00907-w

Table 4.

Trial part 3: adjusted geometric means (Adj. gMean), geometric mean ratios, and 90% confidence intervals (CIs) for the primary pharmacokinetic parameters of digoxin, furosemide, metformin, and rosuvastatin administered as a cocktail with and without the inhibitor probenecid

Endpoint	Test (T)		Reference (R)		Ratio T/R	90% CI	gCV^a
	Cocktail + probenecid		Cocktail alone		Ratio T/R	90% CI	gCV^a
	N	Adj. gMean	N	Adj. gMean	%	%	%
Digoxin
AUC_0–tz (nmol·h/L)	15	14.44	16	13.52	106.78	96.51–118.15	15.5
C_max (nmol/L)	15	1.13	16	1.30	87.07	76.08–99.64	20.9
Furosemide^b
AUC_0–tz (nmol·h/L)	15	483.38	16	177.96	271.63	246.74–299.03	15.9
C_max (nmol/L)	15	110.64	16	90.00	122.94	110.25–137.09	18.0
Metformin
AUC_0-tz (nmol·h/L)	15	1331.83	16	1321.20	100.80	94.62–107.39	9.6
C_max (nmol/L)	15	246.78	16	243.49	101.35	93.65–109.70	12.0
Rosuvastatin
AUC_0–tz (nmol·h/L)	15	238.16	16	106.69	223.24	203.79–244.55	13.9
C_max (nmol/L)	15	43.29	16	10.11	428.23	359.78–509.70	26.8

Endpoint	Test (T)		Reference (R)		Ratio T/R	90% CI	gCV^a
	Furosemide^c + probenecid		Furosemide alone^c		Ratio T/R	90% CI	gCV^a
	N	Adj. gMean	N	Adj. gMean	%	%	%
AUC_0–tz (nmol·h/L)	15	25,741.38	16	8503.07	302.73	274.99–333.27	15.9
C_max (nmol/L)	15	5699.67	16	3887.07	146.63	131.50–163.51	18.0

AUC_0–tz area under the plasma concentration–time curve up to the last quantifiable concentration, C_max maximum plasma concentration, gCV geometric coefficient of variation

^aWithin-subject gCV

^bFurosemide cocktail dose, 1 mg

^cFurosemide therapeutic dose, 40 mg